|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents [note 5] | ||||||||||||||||||||
| Marketable securities [note 5] | ||||||||||||||||||||
| Short-term investments [note 6] | ||||||||||||||||||||
| Grant receivable [note 3] | ||||||||||||||||||||
| Prepaid expenses and other assets | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total prepaid expenses and other assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash and other assets [note 6 and note 7] | ||||||||||||||||||||
| Non-current assets: | ||||||||||||||||||||
| Non-current portion of prepaid expenses and other assets | ||||||||||||||||||||
| Other assets and restricted cash [note 5] | ||||||||||||||||||||
| Right-of-use assets [note 9] | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| License agreement [note 3 and note 4] | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accounts payable | ||||||||||||||||||||
| Accrued liabilities other | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accrued liabilities other | ||||||||||||||||||||
| Contingent consideration [note 5 and note 6] | ||||||||||||||||||||
| Accrued clinical liabilities | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Total accrued clinical liabilities | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Current contingent consideration [note 4 and note 5] | ||||||||||||||||||||
| Current portion of long-term obligations [note 9] | ||||||||||||||||||||
| Current portion of convertible debt [note 5 and note 6] | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Pre-funded warrant liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Non-current portion of convertible debt [note 5 and note 6] | ||||||||||||||||||||
| Non-current contingent consideration [note 4 and note 5] | ||||||||||||||||||||
| Long-term lease liability [note 9] | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Common stock, $0.001 par value, 300,000,000 and 150,000,000 shares authorized at September 30, 2026 and December 31,2025, respectively, 109,776,962 issued and outstanding at September 30, 2026 and 53,233,988 issued and outstanding at December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity |
Loading...